Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6540
    +0.0017 (+0.26%)
     

  • OIL

    84.36
    +0.79 (+0.95%)
     

  • GOLD

    2,360.40
    +17.90 (+0.76%)
     

  • Bitcoin AUD

    97,613.02
    +1,470.29 (+1.53%)
     

  • CMC Crypto 200

    1,384.63
    -11.90 (-0.85%)
     

  • AUD/EUR

    0.6104
    +0.0030 (+0.50%)
     

  • AUD/NZD

    1.0988
    +0.0030 (+0.27%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,116.44
    +37.58 (+0.47%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,078.35
    +161.07 (+0.90%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13

HTG Molecular Diagnostics, Inc.
·1-min read

TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday, May 13, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Conference Call & Webcast Details:

Date:

Thursday, May 13

Time:

4:30 pm Eastern Time

Toll Free:

877-407-0789

International:

201-689-8562

Conference ID:

13719223

Webcast:

http://public.viavid.com/index.php?id=144644

About HTG:

HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com